Name | Number of supported studies | Average coverage | |
---|---|---|---|
Langerhans cell | 3 studies | 61% ± 28% |
Insufficient scRNA-seq data for expression of CD207 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 50% | 79.98 | 122 / 245 | 72% | 5.06 | 359 / 502 |
uterus | 55% | 65.19 | 94 / 170 | 54% | 8.95 | 250 / 459 |
skin | 72% | 1197.82 | 1298 / 1809 | 25% | 1.84 | 116 / 472 |
lung | 29% | 67.38 | 169 / 578 | 57% | 13.54 | 660 / 1155 |
esophagus | 39% | 127.40 | 564 / 1445 | 44% | 5.29 | 81 / 183 |
breast | 27% | 22.73 | 124 / 459 | 53% | 7.28 | 596 / 1118 |
tonsil | 0% | 0 | 0 / 0 | 78% | 15.38 | 35 / 45 |
thymus | 5% | 7.02 | 35 / 653 | 63% | 13.91 | 384 / 605 |
pancreas | 1% | 0.34 | 2 / 328 | 62% | 6.28 | 111 / 178 |
bladder | 10% | 4.14 | 2 / 21 | 32% | 5.04 | 163 / 504 |
ovary | 5% | 2.97 | 9 / 180 | 34% | 3.20 | 148 / 430 |
intestine | 16% | 16.35 | 151 / 966 | 18% | 0.72 | 95 / 527 |
kidney | 2% | 1.66 | 2 / 89 | 31% | 2.52 | 275 / 901 |
stomach | 4% | 2.72 | 13 / 359 | 19% | 0.73 | 53 / 286 |
adipose | 20% | 19.17 | 235 / 1204 | 0% | 0 | 0 / 0 |
spleen | 18% | 15.33 | 43 / 241 | 0% | 0 | 0 / 0 |
brain | 0% | 0.07 | 2 / 2642 | 17% | 0.75 | 117 / 705 |
liver | 1% | 0.45 | 2 / 226 | 14% | 2.08 | 57 / 406 |
adrenal gland | 0% | 0 | 0 / 258 | 12% | 0.48 | 27 / 230 |
eye | 0% | 0 | 0 / 0 | 5% | 0.19 | 4 / 80 |
heart | 4% | 2.96 | 34 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.37 | 1 / 29 |
blood vessel | 2% | 2.25 | 33 / 1335 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.37 | 4 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.10 | 2 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051607 | Biological process | defense response to virus |
GO_0044419 | Biological process | biological process involved in interspecies interaction between organisms |
GO_0031901 | Cellular component | early endosome membrane |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0030139 | Cellular component | endocytic vesicle |
GO_0005537 | Molecular function | D-mannose binding |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CD207 |
Protein name | C-type lectin domain family 4 member K (Langerin) (CD antigen CD207) |
Synonyms | CLEC4K |
Description | FUNCTION: Calcium-dependent lectin displaying mannose-binding specificity. Induces the formation of Birbeck granules (BGs); is a potent regulator of membrane superimposition and zippering. Binds to sulfated as well as mannosylated glycans, keratan sulfate (KS) and beta-glucans. Facilitates uptake of antigens and is involved in the routing and/or processing of antigen for presentation to T cells. Major receptor on primary Langerhans cells for Candida species, Saccharomyces species, and Malassezia furfur. Protects against human immunodeficiency virus-1 (HIV-1) infection. Binds to high-mannose structures present on the envelope glycoprotein which is followed by subsequent targeting of the virus to the Birbeck granules leading to its rapid degradation. . |
Accessions | ENST00000410009.5 Q9UJ71 |